Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer Academic Article uri icon

Overview

MeSH Major

  • Benzoquinones
  • Lactams, Macrocyclic
  • Neoplasms

abstract

  • The MTD and toxicity profile of 17-AAG were schedule dependent. Intermittent dosing schedules were less toxic and are recommended for future phase II studies.

publication date

  • March 15, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3203693

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-1863

PubMed ID

  • 17363532

Additional Document Info

start page

  • 1775

end page

  • 82

volume

  • 13

number

  • 6